Ballentine Partners, LLC Alaunos Therapeutics, Inc. Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding TCRT
# of Institutions
5Shares Held
92.6KCall Options Held
0Put Options Held
0-
Gamble Jones Investment Counsel61KShares$127,4890.0% of portfolio
-
Altium Wealth Management LLC15KShares$31,3490.0% of portfolio
-
Sawtooth Solutions, LLC14.3KShares$29,7820.0% of portfolio
-
American Portfolios Advisors Holbrook, NY2.1KShares$4,3890.0% of portfolio
-
Trustcore Financial Services, LLC250Shares$5220.0% of portfolio
About Alaunos Therapeutics, Inc.
- Ticker TCRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,182,000
- Market Cap $452M
- Description
- Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...